{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:52:37Z","timestamp":1791067957405,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Complicated urinary tract infections (cUTIs), including pyelonephritis, are increasingly challenging when resistant Enterobacterales eliminate conventional oral treatment options. Tebipenem pivoxil (UTEBZI), approved by the US Food and Drug Administration in June 2026, is the first oral carbapenem approved in the United States for selected adults with cUTI. This review evaluates its pharmacology, microbiological activity, efficacy, safety, and potential role in intravenous (IV)-to-oral treatment and antimicrobial stewardship<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A structured narrative review of PubMed\/MEDLINE, regulatory documents, clinical-trial reports, guidelines, pharmacokinetic\/pharmacodynamic studies, microbiological studies, and relevant oral step-down literature was conducted through 12 August 2026. Priority was given to randomized phase 3 trials, FDA prescribing information, and IDSA guidance<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ADAPT-PO and PIVOT-PO demonstrated noninferiority of complete oral tebipenem regimens to IV ertapenem and IV imipenem-cilastatin, respectively, with high clinical cure rates. Tebipenem retains activity against many ESBL- and AmpC-producing Enterobacterales but lacks reliable activity against major carbapenemases. Neither phase 3 trial randomized clinically improving patients after initial IV therapy; therefore, direct randomized evidence for a formal tebipenem step-down strategy is lacking. Important uncertainties include limited bacteremia data, every-six-hour adherence, optimal post-IV duration, cost-effectiveness, microbiome effects, and resistance selection<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tebipenem is an important culture-directed oral option for selected adults with cUTI when narrower effective oral agents are unavailable. Its most defensible early role is replacement of otherwise necessary continued IV carbapenem therapy in carefully selected patients, with source control, susceptibility confirmation, renal doseadjustment, safety screening, duration planning, and stewardship oversight. Dedicated switch, bacteremia, implementation, and resistance-surveillance studies remain needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-026-02991-9","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:07:42Z","timestamp":1791018462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral tebipenem pivoxil for complicated urinary tract infections: evidence, potential role in IV-to-oral transition, and antimicrobial stewardship"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4983-2855","authenticated-orcid":false,"given":"Mohammed","family":"Alkhanafsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamil","family":"Wafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soud","family":"Deek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"2991_CR1","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41585-020-0362-4","volume":"17","author":"FME Wagenlehner","year":"2020","unstructured":"Wagenlehner FME, Bjerklund Johansen TE, Cai T, Koves B, Kranz J, Pilatz A, et al. Epidemiology, definition and treatment of complicated urinary tract infections. Nat Rev Urol. 2020;17:586\u2013600. https:\/\/doi.org\/10.1038\/s41585-020-0362-4.","journal-title":"Nat Rev Urol"},{"key":"2991_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.eururo.2024.05.007","volume":"86","author":"G Bonkat","year":"2024","unstructured":"Bonkat G, Wagenlehner F, Kranz J. Keep it simple: a proposal for a new definition of uncomplicated and complicated urinary tract infections from the EAU Urological Infections Guidelines Panel. Eur Urol. 2024;86:195\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2024.05.007.","journal-title":"Eur Urol"},{"key":"2991_CR3","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.2147\/IDR.S382617","volume":"16","author":"J Marantidis","year":"2023","unstructured":"Marantidis J, Sussman RD. Unmet needs in complicated urinary tract infections: challenges, recommendations, and emerging treatment pathways. Infect Drug Resist. 2023;16:1391\u2013405. https:\/\/doi.org\/10.2147\/IDR.S382617.","journal-title":"Infect Drug Resist"},{"key":"2991_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz446","author":"JJ Carreno","year":"2019","unstructured":"Carreno JJ, Tam IM, Meyers JL, Esterberg E, Candrilli SD, Lodise TP Jr. Longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection. Open Forum Infect Dis. 2019. https:\/\/doi.org\/10.1093\/ofid\/ofz446.","journal-title":"Open Forum Infect Dis"},{"key":"2991_CR5","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.ajic.2021.05.013","volume":"49","author":"TP Lodise","year":"2021","unstructured":"Lodise TP, Chopra T, Nathanson BH, Sulham K. Hospital admission patterns of adult patients with complicated urinary tract infections who present to the hospital by disease acuity and comorbid conditions: how many admissions are potentially avoidable? Am J Infect Control. 2021;49:1528\u201334. https:\/\/doi.org\/10.1016\/j.ajic.2021.05.013.","journal-title":"Am J Infect Control"},{"key":"2991_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac307","author":"TP Lodise","year":"2022","unstructured":"Lodise TP, Manjelievskaia J, Marchlewicz EH, Rodriguez M. Retrospective cohort study of the 12-month epidemiology, treatment patterns, outcomes, and health care costs among adult patients with complicated urinary tract infections. Open Forum Infect Dis. 2022. https:\/\/doi.org\/10.1093\/ofid\/ofac307.","journal-title":"Open Forum Infect Dis"},{"key":"2991_CR7","unstructured":"US Food and Drug Administration. FDA approves first oral carbapenem therapy for complicated urinary tract infections. Published 17 June 2026. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-oral-carbapenem-therapy-complicated-urinary-tract-infections. Accessed 12 Aug 2026."},{"key":"2991_CR8","unstructured":"US Food and Drug Administration. UTEBZI (tebipenem pivoxil) tablets, for oral use: prescribing information. Revised June 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/215960Origs000lbl.pdf. Accessed 12 Aug 2026."},{"key":"2991_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf460","author":"BW Trautner","year":"2025","unstructured":"Trautner BW, Cortes-Penfield NW, Gupta K, Hirsch EB, Horstman M, Moran GJ, et al. Clinical practice guidelines by Infectious Diseases Society of America: 2025 guideline on management and treatment of complicated urinary tract infections\u2014selection of antibiotic therapy for complicated urinary tract infections. Clin Infect Dis. 2025. https:\/\/doi.org\/10.1093\/cid\/ciaf460.","journal-title":"Clin Infect Dis"},{"key":"2991_CR10","doi-asserted-by":"crossref","unstructured":"Tamma PD, Bonomo RA, Heil EL, Justo JA, Satlin MJ, Mathers AJ. IDSA 2026 guidance on the treatment of antimicrobial-resistant gram-negative infections. Infectious Diseases Society of America. Published 30 July 2026. https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance\/. Accessed 12 Aug 2026.","DOI":"10.1093\/cid\/ciag481"},{"key":"2991_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/14787210.2018.1496821","volume":"16","author":"A Jain","year":"2018","unstructured":"Jain A, Utley L, Parr TR Jr, Zabawa T, Pucci MJ. Tebipenem, the first oral carbapenem antibiotic. Expert Rev Anti Infect Ther. 2018;16:513\u201322. https:\/\/doi.org\/10.1080\/14787210.2018.1496821.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2991_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02240-19","author":"N Cotroneo","year":"2020","unstructured":"Cotroneo N, Rubio A, Critchley IA, Pillar C, Pucci MJ. In vitro and in vivo characterization of tebipenem, an oral carbapenem. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/AAC.02240-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"2991_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00603-19","author":"L McEntee","year":"2019","unstructured":"McEntee L, Johnson A, Farrington N, Unsworth J, Dane A, Jain A, et al. Pharmacodynamics of tebipenem: new options for oral treatment of multidrug-resistant gram-negative infections. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/AAC.00603-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"2991_CR14","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa2105462","volume":"386","author":"PB Eckburg","year":"2022","unstructured":"Eckburg PB, Muir L, Critchley IA, Walpole S, Kwak H, Phelan AM, et al. Oral tebipenem pivoxil hydrobromide in complicated urinary tract infection. N Engl J Med. 2022;386:1327\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2105462.","journal-title":"N Engl J Med"},{"key":"2991_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00618-19","author":"PB Eckburg","year":"2019","unstructured":"Eckburg PB, Jain A, Walpole S, Moore G, Utley L, Manyak E, et al. Safety, pharmacokinetics, and food effect of tebipenem pivoxil hydrobromide after single and multiple ascending oral doses in healthy adult subjects. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/AAC.00618-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"2991_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01495-22","author":"G Patel","year":"2023","unstructured":"Patel G, Gupta VK, Gasink L, Bajraktari F, Lei Y, Jain A, et al. Effect of an antacid (aluminum hydroxide\/magnesium hydroxide\/simethicone) or a proton pump inhibitor (omeprazole) on the pharmacokinetics of tebipenem pivoxil hydrobromide (TBP-PI-HBr) in healthy adult subjects. Antimicrob Agents Chemother. 2023. https:\/\/doi.org\/10.1128\/aac.01495-22.","journal-title":"Antimicrob Agents Chemother"},{"key":"2991_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00145-21","author":"VK Gupta","year":"2021","unstructured":"Gupta VK, Maier G, Eckburg P, Morelli L, Lei Y, Jain A, et al. Randomized, double-blind, placebo- and positive-controlled crossover study of the effects of tebipenem pivoxil hydrobromide on QT\/QTc intervals in healthy subjects. Antimicrob Agents Chemother. 2021. https:\/\/doi.org\/10.1128\/AAC.00145-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"2991_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02407-21","author":"G Patel","year":"2022","unstructured":"Patel G, Rodvold KA, Gupta VK, Bruss J, Gasink L, Bajraktari F, et al. Pharmacokinetics of oral tebipenem pivoxil hydrobromide in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 2022. https:\/\/doi.org\/10.1128\/aac.02407-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"2991_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02057-22","author":"RE Mendes","year":"2019","unstructured":"Mendes RE, Arends SJR, Streit JM, Critchley I, Cotroneo N, Castanheira M. Contemporary evaluation of tebipenem in vitro activity against Enterobacterales clinical isolates causing urinary tract infections in US medical centers (2019\u20132020). Microbiol Spectr. 2019. https:\/\/doi.org\/10.1128\/spectrum.02057-22.","journal-title":"Microbiol Spectr"},{"key":"2991_CR20","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01214-22","author":"RE Mendes","year":"2018","unstructured":"Mendes RE, Hubler C, Kimbrough JH, Kantro V, Critchley I, Cotroneo N, et al. In vitro activity of tebipenem against various resistant subsets of Escherichia coli causing urinary tract infections in the United States (2018 to 2020). Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/aac.01214-22.","journal-title":"Antimicrob Agents Chemother"},{"key":"2991_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00042-24","author":"S Sayood","year":"2025","unstructured":"Sayood S, Neuner E, Dumm R, Gandra S. The oral penems and carbapenems. Clin Microbiol Rev. 2025. https:\/\/doi.org\/10.1128\/cmr.00042-24.","journal-title":"Clin Microbiol Rev"},{"key":"2991_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(23)00360-9","author":"T Sewunet","year":"2024","unstructured":"Sewunet T, Razavi M, Rosenborg S, Camporeale A, Nowak M, Melnick D, et al. Effect of tebipenem pivoxil hydrobromide on the normal gut microbiota of a healthy adult population in Sweden: a randomised controlled trial. Lancet Microbe. 2024. https:\/\/doi.org\/10.1016\/S2666-5247(23)00360-9.","journal-title":"Lancet Microbe"},{"key":"2991_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02346-24","author":"MF Mojica","year":"2025","unstructured":"Mojica MF, Hausman BS, Pearlmutter BS, Zink EG, Wilson BM, Villamil V, et al. Impact of tebipenem pivoxil on the intestinal microbiota and on establishment of colonization with carbapenem-resistant Klebsiella pneumoniae in mice. Microbiol Spectr. 2025. https:\/\/doi.org\/10.1128\/spectrum.02346-24.","journal-title":"Microbiol Spectr"},{"key":"2991_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01730-17","author":"K van Loon","year":"2018","unstructured":"van Loon K, Voor in \u2019t holt AF, Vos MC. A systematic review and meta-analyses of the clinical epidemiology of carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.01730-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"2991_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ajic.2015.12.005","volume":"44","author":"J Tischendorf","year":"2016","unstructured":"Tischendorf J, de Avila RA, Safdar N. Risk of infection following colonization with carbapenem-resistant Enterobacteriaceae: a systematic review. Am J Infect Control. 2016;44:539\u201343. https:\/\/doi.org\/10.1016\/j.ajic.2015.12.005.","journal-title":"Am J Infect Control"},{"key":"2991_CR26","doi-asserted-by":"publisher","first-page":"e4607","DOI":"10.1093\/cid\/ciaa1295","volume":"73","author":"AJ Jamal","year":"2021","unstructured":"Jamal AJ, Faheem A, Farooqi L, Zhong XZ, Armstrong I, Boyd DA, et al. Household transmission of carbapenemase-producing Enterobacterales in Ontario, Canada. Clin Infect Dis. 2021;73:e4607\u201315. https:\/\/doi.org\/10.1093\/cid\/ciaa1295.","journal-title":"Clin Infect Dis"},{"key":"2991_CR27","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/jac\/dkaa561","volume":"76","author":"K Marimuthu","year":"2021","unstructured":"Marimuthu K, Mo Y, Ling ML, Hernandez-Koutoucheva A, Fenlon SN, Bertrand D, et al. Household transmission of carbapenemase-producing Enterobacteriaceae: a prospective cohort study. J Antimicrob Chemother. 2021;76:1299\u2013302. https:\/\/doi.org\/10.1093\/jac\/dkaa561.","journal-title":"J Antimicrob Chemother"},{"key":"2991_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf695.003","author":"DK Hong","year":"2026","unstructured":"Hong DK, Ascioglu S, Bhatt N, Critchley IA, Gaber M, Gasink LB, et al. Oral tebipenem pivoxil hydrobromide versus intravenous imipenem-cilastatin in patients with complicated urinary tract infections or acute pyelonephritis: efficacy and safety results from the phase 3 PIVOT-PO study. Open Forum Infect Dis. 2026. https:\/\/doi.org\/10.1093\/ofid\/ofaf695.003.","journal-title":"Open Forum Infect Dis"},{"key":"2991_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00908-22","volume":"67","author":"BD VanScoy","year":"2023","unstructured":"VanScoy BD, Jones S, Conde H, Friedrich LV, Cotroneo N, Bhavnani SM, et al. Evaluation of oral tebipenem as a step-down therapy following intravenous ertapenem against extended-spectrum \u03b2-lactamase-producing Escherichia coli in a hollow-fiber in vitro infection model. Antimicrob Agents Chemother. 2023;67:e00908-22. https:\/\/doi.org\/10.1128\/aac.00908-22.","journal-title":"Antimicrob Agents Chemother"},{"key":"2991_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf461","author":"BW Trautner","year":"2025","unstructured":"Trautner BW, Cortes-Penfield NW, Gupta K, Hirsch EB, Horstman M, Moran GJ, et al. Clinical practice guidelines by Infectious Diseases Society of America: 2025 guidelines on management and treatment of complicated urinary tract infections\u2014timing of intravenous to oral antibiotics transition for complicated urinary tract infections. Clin Infect Dis. 2025. https:\/\/doi.org\/10.1093\/cid\/ciaf461.","journal-title":"Clin Infect Dis"},{"key":"2991_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae193","author":"JJ Veillette","year":"2024","unstructured":"Veillette JJ, May SS, Alzaidi S, Olson J, Butler AM, Waters CD, et al. Real-world effectiveness of intravenous and oral antibiotic stepdown strategies for gram-negative complicated urinary tract infection with bacteremia. Open Forum Infect Dis. 2024. https:\/\/doi.org\/10.1093\/ofid\/ofae193.","journal-title":"Open Forum Infect Dis"},{"key":"2991_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf462","author":"BW Trautner","year":"2025","unstructured":"Trautner BW, Cortes-Penfield NW, Gupta K, Hirsch EB, Horstman M, Moran GJ, et al. Clinical practice guidelines by Infectious Diseases Society of America: 2025 guidelines on management and treatment of complicated urinary tract infections\u2014duration of antibiotics for complicated UTI. Clin Infect Dis. 2025. https:\/\/doi.org\/10.1093\/cid\/ciaf462.","journal-title":"Clin Infect Dis"},{"key":"2991_CR33","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ijantimicag.2016.07.013","volume":"48","author":"LF Kutob","year":"2016","unstructured":"Kutob LF, Justo JA, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN. Effectiveness of oral antibiotics for definitive therapy of Gram-negative bloodstream infections. Int J Antimicrob Agents. 2016;48:498\u2013503. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.07.013.","journal-title":"Int J Antimicrob Agents"},{"key":"2991_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz364","author":"C Punjabi","year":"2019","unstructured":"Punjabi C, Tien V, Meng L, Deresinski S, Holubar M. Oral fluoroquinolone or trimethoprim-sulfamethoxazole vs beta-lactams as step-down therapy for Enterobacteriaceae bacteremia: systematic review and meta-analysis. Open Forum Infect Dis. 2019. https:\/\/doi.org\/10.1093\/ofid\/ofz364.","journal-title":"Open Forum Infect Dis"},{"key":"2991_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116207","volume":"10","author":"ME Falagas","year":"2015","unstructured":"Falagas ME, Karagiannis AKA, Nakouti T, Tansarli GS. Compliance with once-daily versus twice or thrice-daily administration of antibiotic regimens: a meta-analysis of randomized controlled trials. PLoS One. 2015;10:e0116207. https:\/\/doi.org\/10.1371\/journal.pone.0116207.","journal-title":"PLoS One"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02991-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02991-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02991-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:02:29Z","timestamp":1791064949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02991-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":35,"alternative-id":["2991"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02991-9","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"11 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required because this manuscript is a narrative review based exclusively on previously published literature and did not involve human participants, identifiable patient information, or animal subjects.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}